Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 1;77(3):997-1005.
doi: 10.1002/hep.32434. Epub 2023 Feb 17.

Risk factors for HCC in contemporary cohorts of patients with cirrhosis

Affiliations

Risk factors for HCC in contemporary cohorts of patients with cirrhosis

Fasiha Kanwal et al. Hepatology. .

Abstract

Background and aims: Etiological risk factors for cirrhosis have changed in the last decade. It remains unclear to what extent these trends in cirrhosis risk factors have changed HCC risk.

Approach and results: We used data from two contemporary, prospective multiethnic cohorts of patients with cirrhosis: the Texas Hepatocellular Carcinoma Consortium Cohort and the Houston Veterans Administration Cirrhosis Surveillance Cohort. Patients with cirrhosis were enrolled from seven US centers and followed until HCC diagnosis, transplant, death, or June 30, 2021. We calculated the annual incidence rates for HCC and examined the effects of etiology, demographic, clinical, and lifestyle factors on the risk of HCC. We included 2733 patients with cirrhosis (mean age 60.1 years, 31.3% women). At enrollment, 19.0% had active HCV, 23.3% had cured HCV, 16.1% had alcoholic liver disease, and 30.1% had NAFLD. During 7406 person-years of follow-up, 135 patients developed HCC at an annual incidence rate of 1.82% (95% CI, 1.51-2.13). The annual HCC incidence rate was 1.71% in patients with cured HCV, 1.32% in patients with alcoholic liver disease, and 1.24% in patients with NAFLD cirrhosis. Compared to patients with NAFLD, the risk of progression to HCC was 2-fold higher in patients with cured HCV (HR, 2.04; 95% CI, 1.24-3.35). Current smoking (HR, 1.63; 95% CI, 1.01-2.63) and overweight/obesity (HR, 1.79; 95% CI, 1.08-2.95) were also associated with HCC risk.

Conclusions: HCC incidence among patients with cirrhosis was lower than previously reported. HCC risk was variable across etiologies, with higher risk in patients with HCV cirrhosis and lower risk in those with NAFLD cirrhosis. Current smoking and overweight/obesity increased HCC risk across etiologies.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Cumulative incidence of hepatocellular cancer. Hepatitis C virus infection (HCV), nonalcoholic fatty liver disease, alcohol liver disease.

References

    1. Ryerson AB EC, Altekruse SF. Annual Report to the Nation on the Status of Cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122:1312–37. - PMC - PubMed
    1. Moon AM, Singal AG, Tapper EB. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol. Nov 2020;18(12):2650–2666. doi: 10.1016/j.cgh.2019.07.060 - DOI - PMC - PubMed
    1. Jepsen P, Ott P, Andersen PK, Sorensen HT, Vilstrup H. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study. Ann Intern Med. Jun 19 2012;156(12):841–7, W295. doi: 10.7326/0003-4819-156-12-201206190-00004 - DOI - PubMed
    1. Nathalie Ganne-Carrié 1 CC, Bourcier 3 Valérie, Archambeaud 4 Isabelle, Perarnau 5 Jean-Marc, Oberti 6 Frédéric, Roulot 7 Dominique, Moreno 8 Christophe, Louvet 9 Alexandre, Dao 10 Thông, Moirand 11 Romain, Goria 12 Odile, Nguyen-Khac 13 Eric, Carbonell 14 Nicolas, Antonini 15 Térésa, Pol 16 Stanislas, de Ledinghen 17 Victor, Ozenne 18 Violaine, Henrion 19 Jean, Péron 20 Jean-Marie, Tran 21 Albert, Perlemuter 22 Gabriel, Amiot 23 Xavier, Zarski 24 Jean-Pierre, Beaugrand 3 Michel, Chevret 2 Sylvie. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. J Hepatol. 2018;69(6):1274–1283. doi:10.1016 - PubMed
    1. Li DK, Ren Y, Fierer DS, et al. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. Hepatology. Jun 2018;67(6):2244–2253. doi: 10.1002/hep.29707 - DOI - PubMed

Publication types

MeSH terms